Paratek Pharmaceuticals, Inc. /
OptiNose, Inc.
Paratek Pharmaceuticals completes merger with OptiNose




What happened
Paratek Pharmaceuticals, Inc. completed its merger with OptiNose, Inc. on May 21, 2025. OptiNose became a wholly owned subsidiary of Paratek Pharmaceuticals.
OptiNose stockholders became entitled to $9.00 in cash per share and a contractual contingent value right.
The source
Everything on this page comes from the source below.
Paratek Pharmaceuticals completes merger with OptiNose
This document is the source for the companies, stage and people on this page.
Source-verifiedTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Source-verifiedPublished by the source
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly